Denali Therapeutics Stock Fundamentals
| DNLI Stock | USD 15.15 0.26 1.75% |
Denali Therapeutics fundamentals help investors to digest information that contributes to Denali Therapeutics' financial success or failures. It also enables traders to predict the movement of Denali Stock. The fundamental analysis module provides a way to measure Denali Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Denali Therapeutics stock.
As of now, Denali Therapeutics' Total Other Income Expense Net is increasing as compared to previous years. The Denali Therapeutics' current Net Interest Income is estimated to increase to about 67.9 M, while Interest Expense is projected to decrease to under 8.6 M. Denali | Select Account or Indicator |
Denali Therapeutics Company Shares Outstanding Analysis
Denali Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Denali Therapeutics Shares Outstanding | 145.22 M |
Most of Denali Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Denali Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Denali Shares Outstanding Historical Pattern
Today, most investors in Denali Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Denali Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Denali Therapeutics shares outstanding as a starting point in their analysis.
Denali Therapeutics Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Denali Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Denali Therapeutics has 145.22 M of shares currently outstending. This is 19.56% lower than that of the Biotechnology sector and 35.9% higher than that of the Health Care industry. The shares outstanding for all United States stocks is 74.6% higher than that of the company.
Denali Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Denali Therapeutics's current stock value. Our valuation model uses many indicators to compare Denali Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Denali Therapeutics competition to find correlations between indicators driving Denali Therapeutics's intrinsic value. More Info.Denali Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Denali Therapeutics' Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Denali Therapeutics' earnings, one of the primary drivers of an investment's value.Denali Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Denali Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Denali Therapeutics could also be used in its relative valuation, which is a method of valuing Denali Therapeutics by comparing valuation metrics of similar companies.Denali Therapeutics is currently under evaluation in shares outstanding category among its peers.
Denali Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Denali Therapeutics from analyzing Denali Therapeutics' financial statements. These drivers represent accounts that assess Denali Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Denali Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.7B | 9.1B | 3.5B | 2.9B | 3.4B | 2.3B | |
| Enterprise Value | 1.7B | 8.7B | 3.3B | 2.9B | 3.2B | 2.2B |
Denali Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Denali Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Denali Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Denali Fundamentals
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 1.42 B | ||||
| Shares Outstanding | 145.22 M | ||||
| Shares Owned By Insiders | 9.57 % | ||||
| Shares Owned By Institutions | 90.98 % | ||||
| Number Of Shares Shorted | 8.69 M | ||||
| Price To Earning | 60.91 X | ||||
| Price To Book | 1.76 X | ||||
| Price To Sales | 3,644 X | ||||
| Gross Profit | (396.44 M) | ||||
| EBITDA | (487.34 M) | ||||
| Net Income | (422.77 M) | ||||
| Cash And Equivalents | 1.07 B | ||||
| Cash Per Share | 8.66 X | ||||
| Total Debt | 42.29 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 3.20 X | ||||
| Book Value Per Share | 8.53 X | ||||
| Cash Flow From Operations | (347.69 M) | ||||
| Short Ratio | 10.01 X | ||||
| Earnings Per Share | (2.57) X | ||||
| Target Price | 36.63 | ||||
| Number Of Employees | 422 | ||||
| Beta | 1.46 | ||||
| Market Capitalization | 2.2 B | ||||
| Total Asset | 1.37 B | ||||
| Retained Earnings | (1.54 B) | ||||
| Working Capital | 762.23 M | ||||
| Current Asset | 281.74 M | ||||
| Current Liabilities | 10.46 M | ||||
| Net Asset | 1.37 B |
About Denali Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Denali Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Denali Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Denali Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -53.9 M | -51.2 M | |
| Cost Of Revenue | 15.1 M | 14.3 M | |
| Stock Based Compensation To Revenue | 0.29 | 0.28 | |
| Sales General And Administrative To Revenue | 0.36 | 0.34 | |
| Research And Ddevelopement To Revenue | 1.47 | 1.40 | |
| Capex To Revenue | 0.05 | 0.04 | |
| Revenue Per Share | 2.17 | 1.12 | |
| Ebit Per Revenue | (0.54) | (0.56) |
Currently Active Assets on Macroaxis
When determining whether Denali Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Denali Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Denali Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Denali Therapeutics Stock:Check out Denali Therapeutics Piotroski F Score and Denali Therapeutics Altman Z Score analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.